Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Intervalo de año de publicación
1.
J Neurosci ; 36(33): 8757-75, 2016 08 17.
Artículo en Inglés | MEDLINE | ID: mdl-27535920

RESUMEN

UNLABELLED: Amyloid precursor protein (APP) was originally identified as the source of ß-amyloid peptides that accumulate in Alzheimer's disease (AD), but it also has been implicated in the control of multiple aspects of neuronal motility. APP belongs to an evolutionarily conserved family of transmembrane proteins that can interact with a variety of adapter and signaling molecules. Recently, we showed that both APP and its insect ortholog [APPL (APP-Like)] directly bind the heterotrimeric G-protein Goα, supporting the model that APP can function as an unconventional Goα-coupled receptor. We also adapted a well characterized assay of neuronal migration in the hawkmoth, Manduca sexta, to show that APPL-Goα signaling restricts ectopic growth within the developing nervous system, analogous to the role postulated for APP family proteins in controlling migration within the mammalian cortex. Using this assay, we have now identified Manduca Contactin (MsContactin) as an endogenous ligand for APPL, consistent with previous work showing that Contactins interact with APP family proteins in other systems. Using antisense-based knockdown protocols and fusion proteins targeting both proteins, we have shown that MsContactin is selectively expressed by glial cells that ensheath the migratory neurons (expressing APPL), and that MsContactin-APPL interactions normally prevent inappropriate migration and outgrowth. These results provide new evidence that Contactins can function as authentic ligands for APP family proteins that regulate APP-dependent responses in the developing nervous system. They also support the model that misregulated Contactin-APP interactions might provoke aberrant activation of Goα and its effectors, thereby contributing to the neurodegenerative sequelae that typify AD. SIGNIFICANCE STATEMENT: Members of the amyloid precursor protein (APP) family participate in many aspects of neuronal development, but the ligands that normally activate APP signaling have remained controversial. This research provides new evidence that members of the Contactin family function as authentic ligands for APP and its orthologs, and that this evolutionarily conserved class of membrane-attached proteins regulates key aspects of APP-dependent migration and outgrowth in the embryonic nervous system. By defining the normal role of Contactin-APP signaling during development, these studies also provide the framework for investigating how the misregulation of Contactin-APP interactions might contribute to neuronal dysfunction in the context of both normal aging and neurodegenerative conditions, including Alzheimer's disease.


Asunto(s)
Precursor de Proteína beta-Amiloide/metabolismo , Movimiento Celular/fisiología , Contactinas/metabolismo , Regulación del Desarrollo de la Expresión Génica/fisiología , Neuronas/fisiología , Péptidos beta-Amiloides , Precursor de Proteína beta-Amiloide/genética , Animales , Movimiento Celular/efectos de los fármacos , Proteína 1 Similar a ELAV/metabolismo , Embrión no Mamífero , Femenino , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Inmunoprecipitación , Masculino , Manduca , Neuroglía/efectos de los fármacos , Neuroglía/fisiología , Neuronas/efectos de los fármacos , Oligodesoxirribonucleótidos Antisentido/farmacología , ARN Mensajero/metabolismo , Receptor fas/genética , Receptor fas/metabolismo
2.
J Neurosci ; 33(24): 10165-81, 2013 Jun 12.
Artículo en Inglés | MEDLINE | ID: mdl-23761911

RESUMEN

Amyloid precursor protein (APP) belongs to a family of evolutionarily conserved transmembrane glycoproteins that has been proposed to regulate multiple aspects of cell motility in the nervous system. Although APP is best known as the source of ß-amyloid fragments (Aß) that accumulate in Alzheimer's disease, perturbations affecting normal APP signaling events may also contribute to disease progression. Previous in vitro studies showed that interactions between APP and the heterotrimeric G protein Goα-regulated Goα activity and Go-dependent apoptotic responses, independent of Aß. However, evidence for authentic APP-Go interactions within the healthy nervous system has been lacking. To address this issue, we have used a combination of in vitro and in vivo strategies to show that endogenously expressed APP family proteins colocalize with Goα in both insect and mammalian nervous systems, including human brain. Using biochemical, pharmacological, and Bimolecular Fluorescence Complementation assays, we have shown that insect APP (APPL) directly interacts with Goα in cell culture and at synaptic terminals within the insect brain, and that this interaction is regulated by Goα activity. We have also adapted a well characterized assay of neuronal migration in the hawkmoth Manduca to show that perturbations affecting APPL and Goα signaling induce the same unique pattern of ectopic, inappropriate growth and migration, analogous to defective migration patterns seen in mice lacking all APP family proteins. These results support the model that APP and its orthologs regulate conserved aspects of neuronal migration and outgrowth in the nervous system by functioning as unconventional Goα-coupled receptors.


Asunto(s)
Precursor de Proteína beta-Amiloide/metabolismo , Movimiento Celular/fisiología , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/metabolismo , Neuronas/fisiología , Precursor de Proteína beta-Amiloide/genética , Animales , Sitios de Unión/fisiología , Encéfalo/citología , Células COS , Movimiento Celular/efectos de los fármacos , Chlorocebus aethiops , Embrión no Mamífero , Sistema Nervioso Entérico/citología , Femenino , Antagonistas de Receptores de GABA-A/farmacología , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/genética , Guanosina 5'-O-(3-Tiotrifosfato)/farmacología , Humanos , Inmunoprecipitación , Proteínas Luminiscentes/genética , Proteínas Luminiscentes/metabolismo , Masculino , Manduca , Ratones , Morfolinos/farmacología , Mutación/genética , Neuronas/efectos de los fármacos , Picrotoxina/análogos & derivados , Picrotoxina/farmacología , Unión Proteica/fisiología , Sesterterpenos , Transfección
3.
Dis Model Mech ; 4(5): 634-48, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21596710

RESUMEN

A growing body of evidence supports the 'calcium hypothesis' of Alzheimer's disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca(2+)) in the brain, resulting in the progressive symptoms that typify the disease. However, despite ongoing efforts to develop new methods for testing therapeutic compounds that might be beneficial in AD, no single bioassay permits both rapid screening and in vivo validation of candidate drugs that target specific components of the Ca(2+) regulatory machinery. To address this issue, we have integrated four distinct model systems that provide complementary information about a trial compound: the human neuroblastoma MC65 line, which provides an in vitro model of amyloid toxicity; a transgenic Drosophila model, which develops age-dependent pathologies associated with AD; the 3×TgAD transgenic mouse, which recapitulates many of the neuropathological features that typify AD; and the embryonic nervous system of Manduca, which provides a novel in vivo assay for the acute effects of amyloid peptides on neuronal motility. To demonstrate the value of this 'translational suite' of bioassays, we focused on a set of clinically approved dihydropyridines (DHPs), a class of well-defined inhibitors of L-type calcium channels that have been suggested to be neuroprotective in AD. Among the DHPs tested in this study, we found that isradipine reduced the neurotoxic consequences of ß-amyloid accumulation in all four model systems without inducing deleterious side effects. Our results provide new evidence in support of the Ca(2+) hypothesis of AD, and indicate that isradipine represents a promising drug for translation into clinical trials. In addition, these studies also demonstrate that this continuum of bioassays (representing different levels of complexity) provides an effective means of evaluating other candidate compounds that target specific components of the Ca(2+) regulatory machinery and that therefore might be beneficial in the treatment of AD.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Modelos Animales de Enfermedad , Isradipino/uso terapéutico , Investigación Biomédica Traslacional , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/toxicidad , Animales , Bioensayo , Canales de Calcio Tipo L/metabolismo , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Drosophila/efectos de los fármacos , Humanos , Isradipino/administración & dosificación , Isradipino/farmacología , Manduca/efectos de los fármacos , Manduca/embriología , Ratones , Ratones Transgénicos , Neuronas/efectos de los fármacos , Neuronas/patología , Neuronas/ultraestructura , Sustancias Protectoras/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA